NASDAQ
LMDX

LumiraDx Ltd

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

LumiraDx Ltd Stock Price

Vitals

Today's Low:
$0.34
Today's High:
$0.3625
Open Price:
$0.34
52W Low:
$0.3
52W High:
$1.61
Prev. Close:
$0.359
Volume:
19755

Company Statistics

Market Cap.:
$228.60 million
Book Value:
-0.673
Revenue TTM:
$126.52 million
Operating Margin TTM:
-160.01%
Gross Profit TTM:
$61.02 million
Profit Margin:
-267.19%
Return on Assets TTM:
-27.65%
Return on Equity TTM:
-1564.48%

Company Profile

LumiraDx Ltd had its IPO on 2021-09-28 under the ticker symbol LMDX.

The company operates in the Healthcare sector and Diagnostics & Research industry. LumiraDx Ltd has a staff strength of 1,210 employees.

Stock update

Shares of LumiraDx Ltd opened at $0.34 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.34 - $0.36, and closed at $0.35.

This is a -2.51% slip from the previous day's closing price.

A total volume of 19,755 shares were traded at the close of the day’s session.

In the last one week, shares of LumiraDx Ltd have increased by +6.71%.

LumiraDx Ltd's Key Ratios

LumiraDx Ltd has a market cap of $228.60 million, indicating a price to book ratio of 18.6266 and a price to sales ratio of 0.8814.

In the last 12-months LumiraDx Ltd’s revenue was $126.52 million with a gross profit of $61.02 million and an EBITDA of $-175859008. The EBITDA ratio measures LumiraDx Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, LumiraDx Ltd’s operating margin was -160.01% while its return on assets stood at -27.65% with a return of equity of -1564.48%.

In Q2, LumiraDx Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 53%.

LumiraDx Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.98 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into LumiraDx Ltd’s profitability.

LumiraDx Ltd stock is trading at a EV to sales ratio of 1.77 and a EV to EBITDA ratio of -3.075. Its price to sales ratio in the trailing 12-months stood at 0.8814.

LumiraDx Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$340.83 million
Total Liabilities
$89.01 million
Operating Cash Flow
$0
Capital Expenditure
$821000
Dividend Payout Ratio
0%

LumiraDx Ltd ended 2024 with $340.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $340.83 million while shareholder equity stood at $-214609000.00.

LumiraDx Ltd ended 2024 with $0 in deferred long-term liabilities, $89.01 million in other current liabilities, 858429000.00 in common stock, $-1172788000.00 in retained earnings and $4.00 million in goodwill. Its cash balance stood at $25.34 million and cash and short-term investments were $25.34 million. The company’s total short-term debt was $8,849,000 while long-term debt stood at $372.35 million.

LumiraDx Ltd’s total current assets stands at $175.31 million while long-term investments were $11.53 million and short-term investments were $0. Its net receivables were $64.78 million compared to accounts payable of $65.99 million and inventory worth $85.19 million.

In 2024, LumiraDx Ltd's operating cash flow was $0 while its capital expenditure stood at $821000.

Comparatively, LumiraDx Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.35
52-Week High
$1.61
52-Week Low
$0.3
Analyst Target Price
$1.49

LumiraDx Ltd stock is currently trading at $0.35 per share. It touched a 52-week high of $1.61 and a 52-week low of $1.61. Analysts tracking the stock have a 12-month average target price of $1.49.

Its 50-day moving average was $0.4 and 200-day moving average was $0.7 The short ratio stood at 2.11 indicating a short percent outstanding of 0%.

Around 7686.7% of the company’s stock are held by insiders while 2567.5% are held by institutions.

Frequently Asked Questions About LumiraDx Ltd

The stock symbol (also called stock or share ticker) of LumiraDx Ltd is LMDX

The IPO of LumiraDx Ltd took place on 2021-09-28

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$1.13
-0
-0.26%
$243.1
-10.8
-4.25%
$71.82
-2.18
-2.95%
$66.13
0.16
+0.24%
Ocugen Inc (OCGN)
$0.42
0
0%
$429.6
-10.45
-2.37%
$1.5
-0.2
-11.76%
$2349.7
-1.95
-0.08%
Safran SA (SAFRY)
$40.35
0.65
+1.64%
$92.52
-2.4
-2.53%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

Address

3 More London Riverside, London, United Kingdom, SE1 2AQ